Stock Ratings / Health Care / NKTR / dividends

KARD (61) DMRA (47) OMER (46) KRSA (33) ⌘ Pro Terminal →

Nektar Therapeutics (NKTR) Dividend Safety Gauge & 10-Year DRIP Compounder

$39.18 +1.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $39.22

Nektar Therapeutics (NKTR) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.34B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $39.22 (+0.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NKTR)Realized 20D OHLCV Swing Band: ±10.2%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY NKTR SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (33% of score)

20D Institutional Volume Accumulation (±10.2% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (27% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 34.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$41.17-13.1% Next Q

Q2 (-2Q)

Grade E$35.78+4% Next Q

Q3 (-1Q)

Grade E$37.22+5.3% Next Q

Current

Grade E$39.18-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NKTR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NKTR currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($55.69) and Max Pain ($41.14) forces dealer call-delta covering toward $114.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NKTR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NKTR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NKTR)

✓Walkthrough of NKTR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NKTR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.93%📐 HORIZONTAL RANGE

2026-10-30O $39.00H $39.30L $38.00C $39.18VOL 600.9K

RES: $78.22SUP: $30.99SMA50: $55.69SMA200: $65.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NKTR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NKTR Butterfly Map → + Track NKTR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -43.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NKTR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NKTR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NKTR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NKTR)

Health Care Rank #860 of 1016 ⚔️ KARD vs NKTR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NKTR vs. KARD, DMRA, OMER, KRSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nektar Therapeutics (NKTR) ranks #860 by composite RQD confidence (33/100, grade E) and #322 by equity capitalization ($1.34B). Within this direct 5-issuer industry benchmark cohort, NKTR leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NKTR at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NKTR ACTIVE Nektar Therapeutics	E	33/100	—	96.0%	-35.0%	+1.63%	$1.34B	Benchmark Subject
KARD Kardigan Inc.	C-	61/100	—	—	—	+4.22%	$1.34B	/kard-vs-nktr →
DMRA Damora Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.85%	$1.36B	/dmra-vs-nktr →
OMER Omeros Corporation	D	46/100	—	—	-35.0%	+5.98%	$1.37B	/omer-vs-nktr →
KRSA Korsana Biosciences Inc.	E	33/100	—	—	-5.7%	+0.37%	$1.38B	/krsa-vs-nktr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000906709

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nektar Therapeutics (NKTR) reported GAAP revenue of $55.2M (-43.9% vs. FY2024 revenue of $98.4M , and -38.7% cumulative change since FY2023) , GAAP net income of -$164.0M, operating cash flow of -$208.5M, and free cash flow of -$208.7M (-17.8% YoY). On the balance sheet, NKTR closed FY2025 with $280.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$55.2M	-$164.0M	-$208.5M	-$208.7M	$280.4M	—
FY2024 (FY)	2024-12-31	$98.4M	-$119.0M	-$175.7M	-$177.2M	$303.9M	—
FY2023 (FY)	2023-12-31	$90.1M	-$276.0M	-$192.6M	-$192.6M	—	—

3. NKTR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NKTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nektar Therapeutics (NASDAQ: NKTR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $39.18 (+1.63% 1D, market cap $1.34B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NKTR ranks #860 in composite RQD confidence.

How does NKTR compare to KARD and DMRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NKTR carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, KARD (Kardigan Inc.) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $1.34B) and DMRA (Damora Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.36B). Among the 5-stock peer group, NKTR leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NKTR?

Per NKTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000906709), Nektar Therapeutics generated $55.2M in revenue (-43.9% YoY), -$164.0M in net income, and -$208.7M in free cash flow against $280.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NKTR trading relative to its 50-day, 200-day, and 52-week technical levels?

NKTR last traded at $39.18 (+1.63% on volume of 490,385 shares), positioning the stock -29.65% below its 50-day simple moving average ($55.69) and -39.73% below its 200-day simple moving average ($65.01). Across its 52-week range of $33.40 to $109.00, NKTR sits at the 7.6% percentile with a 14-day RSI of 34.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($35.18 to $43.18).

NKTR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does NKTR pay a dividend and is it safe?

Nektar Therapeutics (NKTR) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: NKTR RQD Cockpit NKTR 12M Forecast NKTR Earnings & Move NKTR Dividends & DRIP NKTR Insiders & 13F NKTR Whale Options NKTR Profit Sankey NKTR News & Why